MCID: INT007
MIFTS: 55

Intermediate Coronary Syndrome

Categories: Cardiovascular diseases

Aliases & Classifications for Intermediate Coronary Syndrome

MalaCards integrated aliases for Intermediate Coronary Syndrome:

Name: Intermediate Coronary Syndrome 12 15 17
Unstable Angina 12 15 32
Angina, Unstable 43 71
Myocardial Preinfarction Syndrome 71
Anginal Chest Pain at Rest 12
Impending Infarction 12
Preinfarction Angina 12
Worsening Angina 12
Angina at Rest 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8805
ICD9CM 34 411.1
MeSH 43 D000789
NCIt 49 C66911
ICD10 32 I20.0
UMLS 71 C0002965 C0086666

Summaries for Intermediate Coronary Syndrome

MalaCards based summary : Intermediate Coronary Syndrome, also known as unstable angina, is related to cardiogenic shock and coronary thrombosis, and has symptoms including angina pectoris An important gene associated with Intermediate Coronary Syndrome is PF4 (Platelet Factor 4), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Striated Muscle Contraction. The drugs Nicorandil and Udenafil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Intermediate Coronary Syndrome

Diseases related to Intermediate Coronary Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 31.6 IL6 CRP
2 coronary thrombosis 31.5 SERPINC1 SELP P2RY12 ITGA2B F3
3 proteasome-associated autoinflammatory syndrome 1 31.2 SELP INS IL6 CRP
4 mitral valve insufficiency 31.2 TNNT2 TNNI3 CRP ACE
5 thrombosis 31.1 SERPINC1 SELP PF4 P2RY12 ITGA2B F3
6 coronary artery vasospasm 31.1 TNNI3 CRP ACE
7 aortic aneurysm, familial abdominal, 1 31.0 IL6 CRP ACE
8 heparin-induced thrombocytopenia 31.0 SERPINC1 PF4 F3
9 hypercholesterolemia, familial, 1 31.0 LPA INS CRP COG2 ACE
10 congestive heart failure 31.0 TNNT2 TNNI3 INS IL6 CRP ACE
11 pulmonary edema 30.9 TNNT2 TNNI3 SERPINC1 CRP ACE
12 thrombophilia due to thrombin defect 30.8 SERPINC1 PF4 F3
13 cardiac tamponade 30.8 TNNI3 F3 CRP ACE
14 pericarditis 30.8 TNNT2 TNNI3 IL6 CRP ACE
15 anterolateral myocardial infarction 30.7 MIR142 ACE
16 carotid stenosis 30.7 SELP LPA CRP ACE
17 sudden sensorineural hearing loss 30.6 SERPINC1 IL6
18 thrombocytopenia 30.6 SERPINC1 SELP PF4 ITGA2B IL6 F3
19 peripheral artery disease 30.6 SELP P2RY12 IL6 F3 CRP ACE
20 systolic heart failure 30.6 IL6 CRP ACE
21 background diabetic retinopathy 30.6 INS IL6 ACE
22 factitious disorder 30.6 INS F3
23 coronary stenosis 30.5 TNNI3 IL6 CRP ACE
24 mitral valve stenosis 30.5 SERPINC1 SELP PF4 F3 CRP ACE
25 atherosclerosis susceptibility 30.5 SELP LPA INS IL6 F3 CRP
26 myocardial stunning 30.5 TNNT2 TNNI3 SERPINC1 ACE
27 migraine with or without aura 1 30.5 INS IL6 CRP ACE
28 left bundle branch hemiblock 30.5 TNNT2 TNNT1 TNNI3 P2RY12 ITGA2B CRP
29 acute cystitis 30.5 INS IL6 CRP ACE
30 thrombophlebitis 30.4 SERPINC1 SELP F3 CRP
31 thrombophilia 30.4 SERPINC1 SELP PF4 F3
32 leptin deficiency or dysfunction 30.4 INS IL6 CRP COG2
33 toxic shock syndrome 30.4 SERPINC1 IL6 F3 CRP
34 hypothyroidism 30.4 LPA INS F3 CRP COG2 ACE
35 hypertrophic cardiomyopathy 30.4 TNNT2 TNNT1 TNNI3 ACE
36 heart valve disease 30.4 TNNT2 TNNI3 MIR126 LPA F3 CRP
37 intermittent claudication 30.4 TNNT2 SERPINC1 SELP PF4 IL6 CRP
38 thrombocytosis 30.3 SERPINC1 SELP PF4 IL6 F3 CRP
39 endocarditis 30.3 TNNI3 SERPINC1 PF4 IL6 CRP
40 essential thrombocythemia 30.3 SERPINC1 SELP PF4 ITGA2B IL6 F3
41 antiphospholipid syndrome 30.3 SERPINC1 SELP PF4 F3 CRP
42 lipid metabolism disorder 30.3 MIR126 LPA INS IL6 CRP COG2
43 chronic kidney disease 30.3 TNNT2 TNNI3 LPA INS IL6 CRP
44 end stage renal failure 30.3 SELP IL6 CRP COG2 ACE
45 familial hyperlipidemia 30.2 LPA INS CRP COG2 ACE
46 lung disease 30.2 INS IL6 F3 CRP ACE
47 pulmonary hypertension 30.2 SERPINC1 SELP PF4 IL6 F3 CRP
48 dilated cardiomyopathy 30.1 TNNT2 TNNT1 TNNI3 MB IL6 CRP
49 familial hypercholesterolemia 30.0 LPA INS IL6 CRP COG2 ACE
50 pulmonary embolism 30.0 TNNT2 TNNT1 TNNI3 SERPINC1 PF4 MB

Comorbidity relations with Intermediate Coronary Syndrome via Phenotypic Disease Network (PDN): (show top 50) (show all 101)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Stress Disorder
Allergic Urticaria Angina Pectoris
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Asbestosis Atrioventricular Block
Atrophic Gastritis Basilar Artery Insufficiency
Benign Essential Hypertension Benign Hypertensive Renal Disease
Bleeding Disorder, Platelet-Type, 11 Bronchitis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebrovascular Disease
Chronic Intestinal Vascular Insufficiency Constrictive Pericarditis
Coronary Artery Aneurysm Deficiency Anemia
Diabetic Polyneuropathy Diaphragm Disease
Dressler's Syndrome Duodenitis
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gallbladder Disease
Gastroesophageal Reflux Generalized Atherosclerosis
Gout Heart Disease
Hemopericardium Hyperlipoproteinemia, Type I
Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hypertension, Essential Hypertensive Encephalopathy

Graphical network of the top 20 diseases related to Intermediate Coronary Syndrome:



Diseases related to Intermediate Coronary Syndrome

Symptoms & Phenotypes for Intermediate Coronary Syndrome

UMLS symptoms related to Intermediate Coronary Syndrome:


angina pectoris

MGI Mouse Phenotypes related to Intermediate Coronary Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACE CRP F3 IL6 INS ITGA2B
2 hematopoietic system MP:0005397 9.93 ACE COG2 EEF1A2 F3 IL6 INS
3 homeostasis/metabolism MP:0005376 9.77 ACE COG2 CRP F3 IL6 INS
4 muscle MP:0005369 9.23 EEF1A2 F3 IL6 INS MB TNNI3

Drugs & Therapeutics for Intermediate Coronary Syndrome

Drugs for Intermediate Coronary Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
2
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
9
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
10
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
11
Fondaparinux Approved, Investigational Phase 4 104993-28-4
12
Chromium Approved Phase 4 7440-47-3 27668
13
Citalopram Approved Phase 4 59729-33-8 2771
14
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
15
Ezetimibe Approved Phase 4 163222-33-1 150311
16
Fenofibrate Approved Phase 4 49562-28-9 3339
17
Digoxin Approved Phase 4 20830-75-5 30322 2724385
18
Cangrelor Approved Phase 4 163706-06-7 9854012
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Pravastatin Approved Phase 4 81093-37-0 54687
21
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
22
Desflurane Approved Phase 4 57041-67-5 42113
23
Ramipril Approved Phase 4 87333-19-5 5362129
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Norepinephrine Approved Phase 4 51-41-2 439260
26
Racepinephrine Approved Phase 4 329-65-7 838
27
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
28
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
29
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
30
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
33
Adenosine Approved, Investigational Phase 4 58-61-7 60961
34
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
35
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
36
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
37
Bisoprolol Approved Phase 4 66722-44-9 2405
38
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
39
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
40
Atorvastatin Approved Phase 4 134523-00-5 60823
41
Abciximab Approved Phase 4 143653-53-6
42
Metformin Approved Phase 4 657-24-9 14219 4091
43
Ticagrelor Approved Phase 4 274693-27-5 9871419
44
Dalteparin Approved Phase 4 9005-49-6
45
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
46
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
47
Montelukast Approved Phase 4 158966-92-8 5281040
48
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
49
Tenecteplase Approved Phase 4 191588-94-0
50
Candesartan cilexetil Approved Phase 4 145040-37-5 2540

Interventional clinical trials:

(show top 50) (show all 589)
# Name Status NCT ID Phase Drugs
1 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
2 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
3 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
4 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
5 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
6 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
7 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
8 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
9 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
10 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
11 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
12 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
13 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
14 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
15 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
16 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
17 Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study Unknown status NCT01925027 Phase 4
18 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
19 Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT00476944 Phase 4
20 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
21 A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris Completed NCT02007187 Phase 4 Danhong injection;Placebo
22 The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study Completed NCT02612116 Phase 4 Pulverized ticagrelor sublingually;Pulverized ticagrelor orally;Integral ticagrelor
23 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone - a Randomized Study Completed NCT02939248 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,naloxone
24 Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine Alone - a Randomized Study Completed NCT02939235 Phase 4 Crushed ticagrelor followed by morphine;Crushed ticagrelor, morphine,metoclopramide
25 Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome. Completed NCT00276432 Phase 4
26 Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease Completed NCT00181818 Phase 4 bupropion SR (sustained-release)
27 Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS) Completed NCT00231738 Phase 4 Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)
28 Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
29 Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) – a Randomized Study Comparing a First-Generation With a Second-Generation Stent. Completed NCT00139802 Phase 4
30 Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging Completed NCT01341730 Phase 4 Atorvastatin 20mg;Atorvastatin 20 mg + Pioglitazone 30 mg
31 A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS) Completed NCT00327418 Phase 4 Atorvastatin
32 A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry. Completed NCT01895751 Phase 4
33 Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography Completed NCT00700037 Phase 4 high-dose atorvastatin;low-dose atorvastatin
34 Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up. Completed NCT01637012 Phase 4
35 FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8) Completed NCT00790907 Phase 4 fondaparinux background and standard dose UFH;Fondaparinux background and low dose heparin;Open label fondaparinux
36 Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease Completed NCT00492908 Phase 4
37 Exercise Training Improves Oscillatory Pattern and Arterial Baroreflex Control of Sympathetic Nerve Activity in Patients With Chronic Heart Failure Completed NCT02219451 Phase 4
38 Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT) Completed NCT00190580 Phase 4 valsartan;Conventional antihypertensive drugs
39 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
40 Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial Completed NCT00419471 Phase 4 Escitalopram;Placebo
41 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
42 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
43 A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin Completed NCT02984982 Phase 4 Alirocumab SAR236553;Atorvastatin;Rosuvastatin;Fenofibrate;Bezafibrate;Ezetimibe;Antiplatelets;Anticoagulants
44 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
45 The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT) Completed NCT01331967 Phase 4 Pioglitazone
46 A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study Completed NCT00986050 Phase 4 Abciximab
47 Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent Completed NCT01826552 Phase 4
48 The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial Completed NCT02733341 Phase 4 Cangrelor;Ticagrelor
49 Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI) Completed NCT01293097 Phase 4 Atorvastatin;Statin
50 Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions Completed NCT00735280 Phase 4 unfractionated heparin

Search NIH Clinical Center for Intermediate Coronary Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abciximab
bivalirudin
Dalteparin
Dalteparin Sodium
Enoxaparin
eptifibatide
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
lepirudin
tirofiban
TIROFIBAN HYDROCHLORIDE

Cochrane evidence based reviews: angina, unstable

Genetic Tests for Intermediate Coronary Syndrome

Anatomical Context for Intermediate Coronary Syndrome

MalaCards organs/tissues related to Intermediate Coronary Syndrome:

40
Heart, Testes, Endothelial, Kidney, Lung, Monocytes, Neutrophil

Publications for Intermediate Coronary Syndrome

Articles related to Intermediate Coronary Syndrome:

(show top 50) (show all 12848)
# Title Authors PMID Year
1
Clinical Presentations and Outcomes in Patients Presenting With Acute Cardiac Events and Right Bundle Branch Block. 61
31808355 2020
2
Incidence and Outcomes of Acute Ischemic Stroke Following Percutaneous Coronary Interventions in Men Versus Women. 61
31771757 2020
3
Stress Testing in the Evaluation of Stable Chest Pain in a Community Population. 61
31759674 2020
4
Myocardial Ischemic Burden and Differences in Prognosis Among Patients With and Without Diabetes: Results From the Multicenter International REFINE SPECT Registry. 61
31776140 2020
5
Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia. 61
31601728 2020
6
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. 61
32019364 2020
7
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. 61
31707829 2020
8
Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy. 61
32023582 2020
9
Active Participation in Outpatient Cardiac Rehabilitation Is Associated With Better Prognosis After Coronary Artery Bypass Graft Surgery - J-REHAB CABG Study. 61
32037378 2020
10
Octogenarian preferences and expectations for acute coronary syndrome treatment. 61
32013561 2020
11
Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement. 61
31992059 2020
12
Nationwide trends in acute coronary syndrome by subtype in New Zealand 2006-2016. 61
31672778 2020
13
15-Year lipid profile effects on cardiovascular events adjusted for cardiovascular risk factors: a cohort study from Middle-East. 61
32019473 2020
14
Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review. 61
31919792 2020
15
Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry. 61
29543035 2020
16
Temporal trends in incidence and outcome of acute coronary syndrome. 61
32034482 2020
17
Clinical usefulness of instantaneous wave-free ratio for the evaluation of coronary artery lesion with prior myocardial infarction: A multi-center study. 61
31890864 2020
18
Sleep duration and risk of cardiovascular events: The SAVE study. 61
32013799 2020
19
Blood Platelet Count at Hospital Admission Impacts Long-Term Mortality in Patients with Acute Coronary Syndrome. 61
32018251 2020
20
Feasibility and safety of orbital atherectomy for the treatment of in-stent restenosis secondary to stent under-expansion. 61
31985132 2020
21
Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study. 61
31917789 2020
22
Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: 'The Ottawa Troponin Pathway'. 61
31923216 2020
23
Prognostic value of coronary artery calcium score in symptomatic individuals: A meta-analysis of 34,000 subjects. 61
31229262 2020
24
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. 61
31707324 2020
25
Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. 61
31350546 2020
26
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. 61
31733058 2020
27
Implications of Abnormal Exercise Electrocardiography With Normal Stress Echocardiography. 61
31985749 2020
28
Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus. 61
31902326 2020
29
1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). 61
31709984 2020
30
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. 61
32006518 2020
31
Meta-analysis of C-Reactive Protein and Risk of Angina Pectoris. 61
32014245 2020
32
The correlation between trimethylamine N-oxide, lipoprotein ratios, and conventional lipid parameters in patients with unstable angina pectoris. 61
31894847 2020
33
Guideline adherence and long-term clinical outcomes in patients with acute myocardial infarction: a Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET) substudy. 61
31976749 2020
34
Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting. 61
31432633 2020
35
Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. 61
31713893 2020
36
Effect of Low-Dose Nebivolol in Patients with Acute Myocardial Infarction: A Multi-Center Observational Study. 61
32021843 2020
37
Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. 61
31384933 2020
38
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. 61
31948641 2020
39
Effect of air pollution on the number of hospital admissions for acute coronary syndrome in elderly patients. 61
31742576 2020
40
Clinical outcomes after percutaneous coronary intervention in non-dialysis patients with acute coronary syndrome and advanced renal dysfunction. 61
31903510 2020
41
Dysfunctional HDLs are Associated with a Greater Incidence of Acute Coronary Syndrome in a Population at High Cardiovascular Risk: A Nested-Case Control Study. 61
31941372 2020
42
Temporal Trends Analysis of the Characteristics, Management, and Outcomes of Women With Acute Coronary Syndrome (ACS): ACS Israeli Survey Registry 2000-2016. 61
31852425 2020
43
[Perioperative Outcomes of Patients Undergoing Pulmonary Resection for Lung Cancer after Coronary Stenting]. 61
31948536 2020
44
Pericardial synovial sarcoma presenting with unstable angina. 61
31455084 2020
45
Impact of the introduction of high-sensitive troponin assay in the emergency department: a retrospective study. 61
31987803 2020
46
Evaluation of hs-CRP and sLOX-1 Levels in Moderate-to-High Risk Acute Coronary Syndromes. 61
30961517 2020
47
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. 61
31852422 2020
48
Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 61
31715435 2019
49
Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays. 61
31954328 2019
50
Prognostic significance of coronary artery calcium scoring and single-photon emission computed tomographic myocardial perfusion imaging on major adverse cardiac events in patients at low risk for suspected coronary artery disease. 61
30507290 2019

Variations for Intermediate Coronary Syndrome

Expression for Intermediate Coronary Syndrome

Search GEO for disease gene expression data for Intermediate Coronary Syndrome.

Pathways for Intermediate Coronary Syndrome

Pathways related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.38 TNNT2 TNNI3 INS IL6
2 11.36 TNNT2 TNNT1 TNNI3
3
Show member pathways
11.29 TNNT2 TNNI3 ITGA2B IL6 ACE
4 11.16 TNNT2 TNNI3 INS
5 11.01 SELP LPA IL6

GO Terms for Intermediate Coronary Syndrome

Cellular components related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 SERPINC1 SELP PF4 MIR142 MIR126 INS
2 cardiac myofibril GO:0097512 9.26 TNNT2 TNNI3
3 cardiac Troponin complex GO:1990584 9.16 TNNT2 TNNI3
4 troponin complex GO:0005861 8.8 TNNT2 TNNT1 TNNI3

Biological processes related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 SELP MIR126 INS
2 positive regulation of protein kinase B signaling GO:0051897 9.71 P2RY12 MIR126 INS F3
3 hemostasis GO:0007599 9.61 SERPINC1 P2RY12 F3
4 positive regulation of leukocyte migration GO:0002687 9.55 SELP ITGA2B
5 cardiac muscle contraction GO:0060048 9.54 TNNT2 TNNT1 TNNI3
6 positive regulation of neuroinflammatory response GO:0150078 9.52 MIR142 IL6
7 negative regulation of ATPase activity GO:0032780 9.51 TNNT2 TNNI3
8 muscle filament sliding GO:0030049 9.5 TNNT2 TNNT1 TNNI3
9 negative regulation of blood vessel diameter GO:0097756 9.49 INS CRP
10 negative regulation of lipid storage GO:0010888 9.48 IL6 CRP
11 neutrophil mediated immunity GO:0002446 9.46 IL6 ACE
12 acute-phase response GO:0006953 9.43 INS IL6 CRP
13 skeletal muscle contraction GO:0003009 9.33 TNNT2 TNNT1 TNNI3
14 slow-twitch skeletal muscle fiber contraction GO:0031444 8.96 TNNT1 MB
15 regulation of muscle contraction GO:0006937 8.8 TNNT2 TNNT1 TNNI3

Molecular functions related to Intermediate Coronary Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.56 SERPINC1 SELP PF4 LPA
2 troponin T binding GO:0031014 9.16 TNNT1 TNNI3
3 calcium-dependent ATPase activity GO:0030899 8.96 TNNT2 TNNT1
4 troponin C binding GO:0030172 8.62 TNNT2 TNNI3

Sources for Intermediate Coronary Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....